Global Vascular Endothelial Growth Factor (VEGF) Inhibitors Market 2023-2027

Description

List of Tables

Technavio has been monitoring the vascular endothelial growth factor (VEGF) inhibitors market and is forecast to grow by $ 10400.61 mn during 2022-2027, accelerating at a CAGR of 7.76% during the forecast period. Our report on the vascular endothelial growth factor (VEGF) inhibitors market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high target affinity and specificity of VEGF inhibitors, promising pipeline and expected launches, and strategic alliances.

Technavio's vascular endothelial growth factor (VEGF) inhibitors market is segmented as below:

By Application

Oncology
Ophthalmology

By Type

VEGF-A inhibitor
VEGF-B inhibitor
VEGF-C inhibitor
VEGF-D inhibitor

By Geography

North America
Europe
Asia
Rest of World (ROW)

This study identifies the growing popularity of combination therapies as one of the prime reasons driving the vascular endothelial growth factor (VEGF) inhibitors market growth during the next few years. Also, the development of novel drug delivery systems and growing awareness about oncology and ophthalmology will lead to sizable demand in the market.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on the vascular endothelial growth factor (VEGF) inhibitors market covers the following areas:

Vascular endothelial growth factor (VEGF) inhibitors market sizing
Vascular endothelial growth factor (VEGF) inhibitors market forecast
Vascular endothelial growth factor (VEGF) inhibitors market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading vascular endothelial growth factor (VEGF) inhibitors market vendors that include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bausch Health Co Inc., Bayer AG, Bristol Myers Squibb Co., Clovis Oncology, Eisai Co. Ltd., Eli Lilly and Co., Exelixis Inc., F. Hoffmann La Roche Ltd., LG Chem Ltd., Merck and Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Takeda Pharmaceutical Co. Ltd., Viatris Inc., and Xbrane Biopharma AB. Also, the vascular endothelial growth factor (VEGF) inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Product Code: IRTNTR72445

1 Executive Summary

1.1 Market overview
Exhibit 01: Executive Summary - Chart on Market Overview
Exhibit 02: Executive Summary - Data Table on Market Overview
Exhibit 03: Executive Summary - Chart on Global Market Characteristics
Exhibit 04: Executive Summary - Chart on Market by Geography
Exhibit 05: Executive Summary - Chart on Market Segmentation by Application
Exhibit 06: Executive Summary - Chart on Market Segmentation by Type
Exhibit 07: Executive Summary - Chart on Incremental Growth
Exhibit 08: Executive Summary - Data Table on Incremental Growth
Exhibit 09: Executive Summary - Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem
Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition
Exhibit 12: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 13: Market segments
3.3 Market size 2022
3.4 Market outlook: Forecast for 2022-2027
Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global vascular endothelial growth factor (VEGF) inhibitors market 2017 - 2021
Exhibit 18: Historic Market Size - Data Table on Global vascular endothelial growth factor (VEGF) inhibitors market 2017 - 2021 ($ million)
4.2 Application Segment Analysis 2017 - 2021
Exhibit 19: Historic Market Size - Application Segment 2017 - 2021 ($ million)
4.3 Type Segment Analysis 2017 - 2021
Exhibit 20: Historic Market Size - Type Segment 2017 - 2021 ($ million)
4.4 Geography Segment Analysis 2017 - 2021
Exhibit 21: Historic Market Size - Geography Segment 2017 - 2021 ($ million)
4.5 Country Segment Analysis 2017 - 2021
Exhibit 22: Historic Market Size - Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
5.2 Bargaining power of buyers
Exhibit 24: Chart on Bargaining power of buyers - Impact of key factors 2022 and 2027
5.3 Bargaining power of suppliers
Exhibit 25: Bargaining power of suppliers - Impact of key factors in 2022 and 2027
5.4 Threat of new entrants
Exhibit 26: Threat of new entrants - Impact of key factors in 2022 and 2027
5.5 Threat of substitutes
Exhibit 27: Threat of substitutes - Impact of key factors in 2022 and 2027
5.6 Threat of rivalry
Exhibit 28: Threat of rivalry - Impact of key factors in 2022 and 2027
5.7 Market condition
Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Application

6.1 Market segments
Exhibit 30: Chart on Application - Market share 2022-2027 (%)
Exhibit 31: Data Table on Application - Market share 2022-2027 (%)
6.2 Comparison by Application
Exhibit 32: Chart on Comparison by Application
Exhibit 33: Data Table on Comparison by Application
6.3 Oncology - Market size and forecast 2022-2027
Exhibit 34: Chart on Oncology - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Oncology - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Oncology - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Oncology - Year-over-year growth 2022-2027 (%)
6.4 Ophthalmology - Market size and forecast 2022-2027
Exhibit 38: Chart on Ophthalmology - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Ophthalmology - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Ophthalmology - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Ophthalmology - Year-over-year growth 2022-2027 (%)
6.5 Market opportunity by Application
Exhibit 42: Market opportunity by Application ($ million)

7 Market Segmentation by Type

7.1 Market segments
Exhibit 43: Chart on Type - Market share 2022-2027 (%)
Exhibit 44: Data Table on Type - Market share 2022-2027 (%)
7.2 Comparison by Type
Exhibit 45: Chart on Comparison by Type
Exhibit 46: Data Table on Comparison by Type
7.3 VEGF-A inhibitor - Market size and forecast 2022-2027
Exhibit 47: Chart on VEGF-A inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 48: Data Table on VEGF-A inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 49: Chart on VEGF-A inhibitor - Year-over-year growth 2022-2027 (%)
Exhibit 50: Data Table on VEGF-A inhibitor - Year-over-year growth 2022-2027 (%)
7.4 VEGF-B inhibitor - Market size and forecast 2022-2027
Exhibit 51: Chart on VEGF-B inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 52: Data Table on VEGF-B inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 53: Chart on VEGF-B inhibitor - Year-over-year growth 2022-2027 (%)
Exhibit 54: Data Table on VEGF-B inhibitor - Year-over-year growth 2022-2027 (%)
7.5 VEGF-C inhibitor - Market size and forecast 2022-2027
Exhibit 55: Chart on VEGF-C inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 56: Data Table on VEGF-C inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Chart on VEGF-C inhibitor - Year-over-year growth 2022-2027 (%)
Exhibit 58: Data Table on VEGF-C inhibitor - Year-over-year growth 2022-2027 (%)
7.6 VEGF-D inhibitor - Market size and forecast 2022-2027
Exhibit 59: Chart on VEGF-D inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 60: Data Table on VEGF-D inhibitor - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Chart on VEGF-D inhibitor - Year-over-year growth 2022-2027 (%)
Exhibit 62: Data Table on VEGF-D inhibitor - Year-over-year growth 2022-2027 (%)
7.7 Market opportunity by Type
Exhibit 63: Market opportunity by Type ($ million)

8 Customer Landscape

8.1 Customer landscape overview
Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation
Exhibit 65: Chart on Market share by geography 2022-2027 (%)
Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
9.2 Geographic comparison
Exhibit 67: Chart on Geographic comparison
Exhibit 68: Data Table on Geographic comparison
9.3 North America - Market size and forecast 2022-2027
Exhibit 69: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 70: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 71: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 72: Data Table on North America - Year-over-year growth 2022-2027 (%)
9.4 Europe - Market size and forecast 2022-2027
Exhibit 73: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 74: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 75: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 76: Data Table on Europe - Year-over-year growth 2022-2027 (%)
9.5 Asia - Market size and forecast 2022-2027
Exhibit 77: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 78: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 79: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 80: Data Table on Asia - Year-over-year growth 2022-2027 (%)
9.6 Rest of World (ROW) - Market size and forecast 2022-2027
Exhibit 81: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 82: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 83: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 84: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
9.7 US - Market size and forecast 2022-2027
Exhibit 85: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 86: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 87: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 88: Data Table on US - Year-over-year growth 2022-2027 (%)
9.8 Canada - Market size and forecast 2022-2027
Exhibit 89: Chart on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 90: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
Exhibit 91: Chart on Canada - Year-over-year growth 2022-2027 (%)
Exhibit 92: Data Table on Canada - Year-over-year growth 2022-2027 (%)
9.9 UK - Market size and forecast 2022-2027
Exhibit 93: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 94: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 95: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 96: Data Table on UK - Year-over-year growth 2022-2027 (%)
9.10 Germany - Market size and forecast 2022-2027
Exhibit 97: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 98: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 99: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 100: Data Table on Germany - Year-over-year growth 2022-2027 (%)
9.11 Japan - Market size and forecast 2022-2027
Exhibit 101: Chart on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 102: Data Table on Japan - Market size and forecast 2022-2027 ($ million)
Exhibit 103: Chart on Japan - Year-over-year growth 2022-2027 (%)
Exhibit 104: Data Table on Japan - Year-over-year growth 2022-2027 (%)
9.12 Market opportunity by geography
Exhibit 105: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers
10.2 Market challenges
10.3 Impact of drivers and challenges
Exhibit 106: Impact of drivers and challenges in 2022 and 2027
10.4 Market trends

11 Vendor Landscape

11.1 Overview
11.2 Vendor landscape
Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
11.3 Landscape disruption
Exhibit 108: Overview on factors of disruption
11.4 Industry risks
Exhibit 109: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered
Exhibit 110: Vendors covered
12.2 Market positioning of vendors
Exhibit 111: Matrix on vendor position and classification
12.3 AbbVie Inc.
Exhibit 112: AbbVie Inc. - Overview
Exhibit 113: AbbVie Inc. - Product / Service
Exhibit 114: AbbVie Inc. - Key news
Exhibit 115: AbbVie Inc. - Key offerings
12.4 Amgen Inc.
Exhibit 116: Amgen Inc. - Overview
Exhibit 117: Amgen Inc. - Product / Service
Exhibit 118: Amgen Inc. - Key offerings
12.5 AstraZeneca Plc
Exhibit 119: AstraZeneca Plc - Overview
Exhibit 120: AstraZeneca Plc - Product / Service
Exhibit 121: AstraZeneca Plc - Key news
Exhibit 122: AstraZeneca Plc - Key offerings
12.6 Bausch Health Co Inc.
Exhibit 123: Bausch Health Co Inc. - Overview
Exhibit 124: Bausch Health Co Inc. - Business segments
Exhibit 125: Bausch Health Co Inc. - Key news
Exhibit 126: Bausch Health Co Inc. - Key offerings
Exhibit 127: Bausch Health Co Inc. - Segment focus
12.7 Bayer AG
Exhibit 128: Bayer AG - Overview
Exhibit 129: Bayer AG - Business segments
Exhibit 130: Bayer AG - Key news
Exhibit 131: Bayer AG - Key offerings
Exhibit 132: Bayer AG - Segment focus
12.8 Bristol Myers Squibb Co.
Exhibit 133: Bristol Myers Squibb Co. - Overview
Exhibit 134: Bristol Myers Squibb Co. - Product / Service
Exhibit 135: Bristol Myers Squibb Co. - Key news
Exhibit 136: Bristol Myers Squibb Co. - Key offerings
12.9 Eisai Co. Ltd.
Exhibit 137: Eisai Co. Ltd. - Overview
Exhibit 138: Eisai Co. Ltd. - Business segments
Exhibit 139: Eisai Co. Ltd. - Key news
Exhibit 140: Eisai Co. Ltd. - Key offerings
Exhibit 141: Eisai Co. Ltd. - Segment focus
12.10 Eli Lilly and Co.
Exhibit 142: Eli Lilly and Co. - Overview
Exhibit 143: Eli Lilly and Co. - Product / Service
Exhibit 144: Eli Lilly and Co. - Key offerings
12.11 F. Hoffmann La Roche Ltd.
Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus
12.12 Merck and Co. Inc.
Exhibit 150: Merck and Co. Inc. - Overview
Exhibit 151: Merck and Co. Inc. - Business segments
Exhibit 152: Merck and Co. Inc. - Key news
Exhibit 153: Merck and Co. Inc. - Key offerings
Exhibit 154: Merck and Co. Inc. - Segment focus
12.13 Novartis AG
Exhibit 155: Novartis AG - Overview
Exhibit 156: Novartis AG - Business segments
Exhibit 157: Novartis AG - Key offerings
Exhibit 158: Novartis AG - Segment focus
12.14 Pfizer Inc.
Exhibit 159: Pfizer Inc. - Overview
Exhibit 160: Pfizer Inc. - Product / Service
Exhibit 161: Pfizer Inc. - Key news
Exhibit 162: Pfizer Inc. - Key offerings
12.15 Regeneron Pharmaceuticals Inc.
Exhibit 163: Regeneron Pharmaceuticals Inc. - Overview
Exhibit 164: Regeneron Pharmaceuticals Inc. - Product / Service
Exhibit 165: Regeneron Pharmaceuticals Inc. - Key offerings
12.16 Sanofi SA
Exhibit 166: Sanofi SA - Overview
Exhibit 167: Sanofi SA - Business segments
Exhibit 168: Sanofi SA - Key news
Exhibit 169: Sanofi SA - Key offerings
Exhibit 170: Sanofi SA - Segment focus
12.17 Takeda Pharmaceutical Co. Ltd.
Exhibit 171: Takeda Pharmaceutical Co. Ltd. - Overview
Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Product / Service
Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Key news
Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key offerings

13 Appendix

13.1 Scope of the report
13.2 Inclusions and exclusions checklist
Exhibit 175: Inclusions checklist
Exhibit 176: Exclusions checklist
13.3 Currency conversion rates for US$
Exhibit 177: Currency conversion rates for US$
13.4 Research methodology
Exhibit 178: Research methodology
Exhibit 179: Validation techniques employed for market sizing
Exhibit 180: Information sources
13.5 List of abbreviations
Exhibit 181: List of abbreviations